Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 34 | 2021 | 2535 | 1.790 |
Why?
|
| Cognition Disorders | 4 | 2013 | 243 | 1.080 |
Why?
|
| Anti-HIV Agents | 10 | 2018 | 475 | 0.970 |
Why?
|
| Monocytes | 11 | 2018 | 275 | 0.910 |
Why?
|
| Cerebrovascular Disorders | 2 | 2012 | 43 | 0.710 |
Why?
|
| HIV-1 | 8 | 2018 | 747 | 0.580 |
Why?
|
| Cognition | 5 | 2018 | 458 | 0.510 |
Why?
|
| Middle Aged | 37 | 2021 | 11819 | 0.510 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 229 | 0.490 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 22 | 0.480 |
Why?
|
| Anti-Retroviral Agents | 7 | 2018 | 158 | 0.480 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 49 | 0.470 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 56 | 0.470 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 303 | 0.450 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 14 | 0.420 |
Why?
|
| Male | 42 | 2021 | 22779 | 0.420 |
Why?
|
| Mucuna | 1 | 2013 | 2 | 0.410 |
Why?
|
| Dizziness | 1 | 2013 | 6 | 0.410 |
Why?
|
| Levodopa | 1 | 2013 | 26 | 0.400 |
Why?
|
| Headache Disorders, Primary | 1 | 2013 | 1 | 0.400 |
Why?
|
| Abdominal Pain | 1 | 2013 | 25 | 0.400 |
Why?
|
| Post-Traumatic Headache | 1 | 2013 | 5 | 0.400 |
Why?
|
| Hippocampus | 2 | 2016 | 591 | 0.390 |
Why?
|
| Female | 41 | 2021 | 24018 | 0.380 |
Why?
|
| Dementia | 2 | 2014 | 155 | 0.380 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 22 | 0.380 |
Why?
|
| Brain Injuries | 1 | 2013 | 133 | 0.340 |
Why?
|
| Viral Load | 4 | 2021 | 344 | 0.340 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 13 | 0.330 |
Why?
|
| Humans | 44 | 2021 | 42163 | 0.320 |
Why?
|
| Adult | 24 | 2021 | 13458 | 0.320 |
Why?
|
| Aging | 6 | 2016 | 764 | 0.300 |
Why?
|
| Multilingualism | 1 | 2009 | 50 | 0.300 |
Why?
|
| Cross-Sectional Studies | 16 | 2021 | 3077 | 0.290 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 532 | 0.270 |
Why?
|
| Cardiovascular Diseases | 4 | 2016 | 729 | 0.270 |
Why?
|
| Central Nervous System | 2 | 2018 | 150 | 0.250 |
Why?
|
| RNA, Viral | 3 | 2018 | 317 | 0.250 |
Why?
|
| Depression | 1 | 2013 | 837 | 0.240 |
Why?
|
| Lipoproteins | 3 | 2014 | 68 | 0.240 |
Why?
|
| Viremia | 2 | 2018 | 44 | 0.230 |
Why?
|
| Inflammation | 5 | 2018 | 729 | 0.230 |
Why?
|
| Macrophages | 3 | 2014 | 515 | 0.230 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2021 | 200 | 0.220 |
Why?
|
| Neuropsychological Tests | 5 | 2018 | 281 | 0.210 |
Why?
|
| Hawaii | 9 | 2018 | 2004 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 577 | 0.200 |
Why?
|
| Aged | 9 | 2021 | 7982 | 0.200 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 12 | 0.190 |
Why?
|
| Brain | 3 | 2021 | 1452 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2013 | 165 | 0.190 |
Why?
|
| Risk Factors | 8 | 2015 | 3942 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2015 | 1574 | 0.180 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 2803 | 0.180 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 64 | 0.170 |
Why?
|
| DNA, Viral | 2 | 2013 | 323 | 0.170 |
Why?
|
| Prevalence | 2 | 2017 | 1597 | 0.160 |
Why?
|
| Atrophy | 3 | 2016 | 51 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2016 | 246 | 0.160 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 14 | 0.150 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 22 | 0.150 |
Why?
|
| Benzoxazines | 1 | 2018 | 46 | 0.150 |
Why?
|
| Galectins | 1 | 2018 | 29 | 0.150 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 28 | 0.150 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 32 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2018 | 122 | 0.140 |
Why?
|
| Leukoaraiosis | 2 | 2008 | 2 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 146 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| AIDS Dementia Complex | 3 | 2014 | 116 | 0.140 |
Why?
|
| Headache | 1 | 2017 | 21 | 0.130 |
Why?
|
| Neurocysticercosis | 1 | 2017 | 29 | 0.130 |
Why?
|
| Epilepsy | 1 | 2017 | 56 | 0.130 |
Why?
|
| Blood Glucose | 3 | 2014 | 386 | 0.130 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 378 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 37 | 0.120 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 25 | 0.120 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.120 |
Why?
|
| Brachial Artery | 1 | 2015 | 27 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2008 | 196 | 0.120 |
Why?
|
| Amblyopia | 1 | 2015 | 13 | 0.120 |
Why?
|
| Vasodilation | 1 | 2015 | 64 | 0.120 |
Why?
|
| Coronary Vessels | 1 | 2016 | 92 | 0.120 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.120 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 21 | 0.120 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 34 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 95 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 438 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1266 | 0.110 |
Why?
|
| Cyclohexanes | 1 | 2014 | 30 | 0.110 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 48 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 185 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 66 | 0.110 |
Why?
|
| Comorbidity | 2 | 2016 | 725 | 0.110 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2014 | 31 | 0.100 |
Why?
|
| Triazoles | 1 | 2014 | 100 | 0.100 |
Why?
|
| Polyneuropathies | 1 | 2013 | 9 | 0.100 |
Why?
|
| Carotid Arteries | 1 | 2013 | 35 | 0.100 |
Why?
|
| Reflex | 1 | 2013 | 29 | 0.100 |
Why?
|
| Social Work | 1 | 2013 | 51 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 74 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 2013 | 28 | 0.100 |
Why?
|
| Chronic Disease | 2 | 2015 | 541 | 0.100 |
Why?
|
| Tension-Type Headache | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cholesterol | 1 | 2014 | 230 | 0.100 |
Why?
|
| Niacin | 1 | 2013 | 23 | 0.100 |
Why?
|
| Migraine Disorders | 1 | 2013 | 9 | 0.100 |
Why?
|
| Calcium | 1 | 2016 | 487 | 0.100 |
Why?
|
| Albuminuria | 1 | 2013 | 78 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 78 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2016 | 393 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 238 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2014 | 180 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 225 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 708 | 0.090 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 13 | 0.090 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 38 | 0.090 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 27 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2016 | 990 | 0.090 |
Why?
|
| Insulin Resistance | 1 | 2014 | 199 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.090 |
Why?
|
| Eating | 1 | 2013 | 164 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 280 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2011 | 56 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.090 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 156 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2017 | 2485 | 0.090 |
Why?
|
| Hospitalization | 1 | 2014 | 482 | 0.090 |
Why?
|
| Mitochondria | 1 | 2014 | 516 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2014 | 1729 | 0.080 |
Why?
|
| Memory | 1 | 2012 | 175 | 0.080 |
Why?
|
| Educational Status | 1 | 2012 | 335 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2013 | 324 | 0.080 |
Why?
|
| HIV Seropositivity | 2 | 2013 | 196 | 0.080 |
Why?
|
| Logistic Models | 1 | 2013 | 1001 | 0.080 |
Why?
|
| Cell Movement | 1 | 2013 | 640 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 2009 | 65 | 0.080 |
Why?
|
| Papilledema | 1 | 2009 | 1 | 0.080 |
Why?
|
| Pseudotumor Cerebri | 1 | 2009 | 2 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1008 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2013 | 916 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 300 | 0.070 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2008 | 2 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 163 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2009 | 61 | 0.070 |
Why?
|
| Phenotype | 3 | 2016 | 774 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2018 | 733 | 0.070 |
Why?
|
| Time Factors | 1 | 2013 | 1848 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 24 | 0.070 |
Why?
|
| Incidence | 1 | 2010 | 1054 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 1020 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2018 | 68 | 0.060 |
Why?
|
| Age Factors | 3 | 2018 | 1139 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.060 |
Why?
|
| Zidovudine | 2 | 2015 | 31 | 0.050 |
Why?
|
| Receptors, IgG | 2 | 2014 | 53 | 0.050 |
Why?
|
| Atherosclerosis | 2 | 2014 | 164 | 0.050 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2018 | 42 | 0.040 |
Why?
|
| Alkynes | 1 | 2018 | 50 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 845 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2018 | 59 | 0.040 |
Why?
|
| Taenia solium | 1 | 2017 | 5 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2013 | 662 | 0.030 |
Why?
|
| HIV | 1 | 2016 | 100 | 0.030 |
Why?
|
| Los Angeles | 1 | 2017 | 390 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 574 | 0.030 |
Why?
|
| Stavudine | 1 | 2015 | 13 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 61 | 0.030 |
Why?
|
| Leg | 1 | 2015 | 19 | 0.030 |
Why?
|
| Thailand | 1 | 2015 | 51 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 244 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 181 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 246 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 47 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 68 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 348 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 185 | 0.030 |
Why?
|
| Particle Size | 1 | 2014 | 267 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 91 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 31 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 358 | 0.030 |
Why?
|
| Oxygen | 1 | 2014 | 217 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2013 | 74 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 850 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 661 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 518 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 289 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 133 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 72 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 113 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 1143 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 973 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 57 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 692 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 379 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1066 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1516 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4936 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 261 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 661 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1586 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2008 | 58 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 101 | 0.020 |
Why?
|
| Survivors | 1 | 2008 | 152 | 0.020 |
Why?
|
| Linear Models | 1 | 2007 | 311 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 245 | 0.020 |
Why?
|
| Hypertension | 1 | 2008 | 823 | 0.010 |
Why?
|
| Smoking | 1 | 2008 | 1019 | 0.010 |
Why?
|
| Child | 1 | 2009 | 3381 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 16695 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 5950 | 0.010 |
Why?
|